Phase 2 Cystic Fibrosis Trial, Recruiting NCT06775340 Sponsor: Jiangsu HengRui Medicine Co., Ltd. Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Phase 2 Cystic Fibrosis Trial, Recruiting

NCT06775340
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (inclusive), either male or female
  • If you are female, you weigh at least 45 kg (about 99 lbs); if you are male, you weigh at least 50 kg (about 110 lbs)
  • A special lung scan (HRCT) has shown bronchiectasis (widening/damage of the airways) in one or more parts of your lungs, and a doctor has confirmed this is not related to cystic fibrosis
  • You are expected to live for more than 12 months
  • You are willing and able to sign a consent form before the trial begins
  • If you are able to have children, you are willing to use appropriate contraception during the trial

Who may not be able to join:

  • You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), COPD, or asthma as your main lung condition
  • You currently have an active respiratory virus infection, such as COVID-19 or flu, with symptoms
  • You have psoriasis or lichen planus (certain skin conditions)
  • You have certain skin or joint conditions including Wright's disease, keratosis, hemorrhagic keratosis, or reactive arthritis (confirm with trial site)
  • You have chlorine acne, large common warts, or keratodermatitis (certain skin conditions) (confirm with trial site)
  • You have a diabetic foot condition
  • You have gum disease, an oral infection, or loose teeth
  • You have had a cancer diagnosis within the past 5 years
  • You have a history of liver disease or are currently being treated for liver problems, including hepatitis, cirrhosis, or liver failure
  • You have any other unstable medical condition, as judged by the trial doctors
  • You have taken oral or inhaled antibiotics in the 4 weeks before starting the trial
  • You have taken immune-suppressing medications in the 4 weeks before starting the trial
  • You have taken any medications that may cause skin thickening in the 4 weeks before screening (confirm with trial site)
  • You have received a live vaccine (such as certain flu or travel vaccines) within 30 days before starting the trial
  • You have taken part in a medical device clinical trial within the past 3 months
  • You have an active hepatitis B or C infection, HIV, or syphilis
  • You currently misuse drugs
  • You are a current smoker, or you stopped smoking less than 3 months ago
  • You are known or suspected to be allergic to the trial drug or any of its ingredients, or you have had a severe allergic reaction to any drug, food, or other substance
  • You are pregnant or breastfeeding
  • You are unable to complete questionnaires or forms yourself, and neither you nor a family member is able to fill in a study log (confirm with trial site)
  • The trial doctors decide there is any other reason that makes participation unsuitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +0518-81220121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
22 January 2025
Est. completion
1 November 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The number of occurrences of AEs; the frequency of occurrence of AEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov